Company intelligence / Profile preview

Seom

Montcada i Reixac*, Catalonia, Spainseommusic.de ↗

Ownership: Private
Development stage: Other

Overview

Lead product SOM3355 suited for the treatment of movement disorders and psychiatric disorders, successfully completed a Phase 2b in patients with Huntington’s chorea. The study demonstrated robust improvements of chorea symptoms with a favorable safety profile.

Therapeutic areas: Neurology
Modalities: Small moleculeArtificial Intelligence-based drug discovery platform
Industry: Biotech

Partnerships

Multiple industry partnerships and academic collaborations mentioned but not named specifically.

Beyond the preview

Go deeper on Seom.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seom.

Explore the full profile